부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Lurasidone
JM-010
SOL-804
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Lurasidone
JM-010
SOL-804
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
R&D news | Last Patient Enrolled in the ASTORIA Phase 2b Clinical Trial..
Contera Pharma A/S, a biotech company developing innovative therapies to treat n..
2024.01.17
R&D news | Bukwang Pharmaceutical receives approval for LATUDA, a treat..
Bukwang Pharmaceutical announced the approval of LATUDA (lurasidone hydrochlorid..
2023.11.24
R&D news | Bukwang announces patent registration of SOL-804 in 32 coun..
-registration in more 6 countries, including Korea in this yearBukwang Pharmaceu..
2022.08.09
R&D news | Bukwang Announces the result of SOL-804’s Phase 1 clinical ..
Result : It has similar pharmacokinetic properties with low-doses compared to th..
2022.03.30
R&D news | Bukwang Announces Completion of SOL-804’s Phase 1 clinical ..
- The result will be shown in March : to confirm the equivalent effectiveness wi..
2022.02.25
Company news | Bukwang accelerates globalization together with OCI
-Aiming to become a global pharma through synergy between the two companies-On 2..
2022.02.22
1
2
3
4
5